ArticleFrontiers in oncology2026

Case Report: Site-specific therapy guided by the 90-gene expression assay in cancer of unknown primary: lenvatinib plus camrelizumab for occult renal cell carcinoma.

Liangshan Da et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.